- Home
- ECBK vs CGEN Comparison
ECBK vs CGEN Comparison
Compare ECBK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ECBK | CGEN |
|---|---|---|
| Founded | 1919 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.5M | 191.1M |
| IPO Year | 2022 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ECBK | CGEN |
|---|---|---|
| Price | $20.62 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 6.4K | ★ 283.7K |
| Earning Date | 05-12-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 95.83 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $598,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $26.95 | ★ N/A |
| Revenue Growth | ★ 3.64 | N/A |
| 52 Week Low | $14.83 | $1.30 |
| 52 Week High | $21.53 | $3.24 |
Technical Indicators
Market Signals| Indicator | ECBK | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 47.57 | 46.78 |
| Support Level | $20.12 | $2.20 |
| Resistance Level | $20.79 | $2.54 |
| Average True Range (ATR) | 0.53 | 0.08 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 28.79 | 29.31 |
Price Performance
Historical ComparisonAbout ECBK ECB Bancorp Inc.
ECB Bancorp Inc operates as a bank holding company. The firm, through its subsidiary, engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, multifamily real estate loans, construction and land loans, and home equity lines of credit.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.